Every year, billions of euros in pharmaceutical procurement value shifts from branded drug budgets to competitive tender processes across the […]

Methods-of-use patents have quietly become the pharmaceutical industry’s most underappreciated exclusivity tool. Here’s how they work, who’s using them, and

The Window You Cannot Miss Every drug patent that expires is a commercial event for at least a dozen industries.

The FDA lets you extend only one patent per drug approval. Most companies leave years of exclusivity on the table

There is a persistent gap between what Western pharmaceutical executives think they know about drug patent protection in Eurasia and

A Strategic Guide for Pharmaceutical IP Professionals, Formulation Scientists, and Generic Drug Developers Introduction: Why Patent Claims Decide Who Wins

Every pharmaceutical patent starts its life with a 20-year timer running from the filing date. By the time a new

Every patent portfolio in the pharmaceutical industry contains dead weight. Not metaphorically — literally. Compounds whose commercial logic evaporated years

Launching a drug without a freedom-to-operate analysis is like building a factory on land you haven’t verified you own. You